The Global Real World Evidence Solutions Market size is expected to reach $65.1 billion by 2028, rising at a market growth of 8.0% CAGR during the forecast period.
In medicine, clinical evidence about the use and possible advantages or dangers of a medical product that is produced from a study of real-world data (RWD) is known as real-world evidence (RWE). Different analyses or study designs, such as randomized trials, including pragmatic trials, large simple trials, and prospective or retrospective observational studies, among others, might produce RWE. When clinical trials cannot adequately represent the whole patient population for a given disease, real-world evidence is required.
Patients who did not take part in any clinical trials, have comorbid conditions, reside in a remote location, or are older than the recommended age range may not react to the medication in consideration as expected. RWE offers solutions to these issues as well as the ability to examine the effects of medications over a longer time frame. Pharmaceutical businesses, as well as health insurance payers, research RWE in order to comprehend patient pathways, provide appropriate care for the right people, and reduce their financial risk by funding patient-effective drugs.
The World Ageing Population report estimates that 703 million individuals worldwide were 65 years of age or older in 2019, and that figure is projected to rise to 1.5 billion by 2050. According to estimates, cancer, obesity, cardiovascular diseases, and diabetes, all of which are on the rise, are responsible for over half of all fatalities from chronic diseases. Pharmaceutical corporations spend billions on research & development with a minimal chance of success before bringing a new medication molecule to market.
Pharma research facilities need a strong understanding of treatment choices that are effective across a large population as opposed to small patient groups in clinical trials if they are to shorten drug development cycles. Thus, it is discovered that the usage of real-world evidence (RWE) findings is growing. This is because pharmaceuticals and biotech companies are becoming more aware of the potential value of RWE in life-cycle management and drug development, as well as how it can lower the cost of clinical trials and boost innovation efficiency.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include IBM Corporation, Oracle Corporation, Medpace Holdings, Inc., IQVIA Holdings, Inc., ICON plc, PerkinElmer, Inc., Parexel International Corporation (Phoenix Parentco, Inc.), PPD, Inc. (Thermo Fisher Scientific, Inc.), UnitedHealth Group, Inc. (Optum, Inc.), and Syneos Health, Inc.
In medicine, clinical evidence about the use and possible advantages or dangers of a medical product that is produced from a study of real-world data (RWD) is known as real-world evidence (RWE). Different analyses or study designs, such as randomized trials, including pragmatic trials, large simple trials, and prospective or retrospective observational studies, among others, might produce RWE. When clinical trials cannot adequately represent the whole patient population for a given disease, real-world evidence is required.
Patients who did not take part in any clinical trials, have comorbid conditions, reside in a remote location, or are older than the recommended age range may not react to the medication in consideration as expected. RWE offers solutions to these issues as well as the ability to examine the effects of medications over a longer time frame. Pharmaceutical businesses, as well as health insurance payers, research RWE in order to comprehend patient pathways, provide appropriate care for the right people, and reduce their financial risk by funding patient-effective drugs.
The World Ageing Population report estimates that 703 million individuals worldwide were 65 years of age or older in 2019, and that figure is projected to rise to 1.5 billion by 2050. According to estimates, cancer, obesity, cardiovascular diseases, and diabetes, all of which are on the rise, are responsible for over half of all fatalities from chronic diseases. Pharmaceutical corporations spend billions on research & development with a minimal chance of success before bringing a new medication molecule to market.
Pharma research facilities need a strong understanding of treatment choices that are effective across a large population as opposed to small patient groups in clinical trials if they are to shorten drug development cycles. Thus, it is discovered that the usage of real-world evidence (RWE) findings is growing. This is because pharmaceuticals and biotech companies are becoming more aware of the potential value of RWE in life-cycle management and drug development, as well as how it can lower the cost of clinical trials and boost innovation efficiency.
COVID-19 Impact Analysis
The infectious coronavirus could economically impact most industries, including the pharmaceutical sector. Many medical professionals and pharmaceutical companies have used their resources to stop the COVID-19 pandemic's spread and create efficient drugs and vaccinations. Thus, a tendency toward patient-centered virtual care and digitalization is being observed in the industry. This highlights the requirement for practical, workable solutions. Two prominent healthcare data science firms, Aetion and HealthVerity, were discovered partnering in 2020, strengthening their already established partnership to extract practical medical evidence from EHRs (electronic health records) and counsel drug producers and authorities on COVID-19 treatments.Market Growth Factors
Rising investment in R&D to create new goods and medical devices along with lowering the price of medication development
Most biopharmaceutical, pharmaceutical, and medical device businesses continue to make significant investments in creating new medications and equipment. R&D is very important in the pharmaceutical business in particular. Pharmaceutical and biopharmaceutical businesses are choosing fully functional or integrated outsourcing services from the early development phase to the late-stage development phase to meet the requirements for drug development and discovery due to their increasing R&D spending. The pharmaceutical sector of the economy spends the highest proportion of its profits on research and development.Increased emphasis on comprehensive RWE services
Healthcare stakeholders are looking for new solutions to deal with the unaffordable financial burden and relatively low return on investment, transforming the healthcare ecosystem and raising concerns about healthcare prices. Businesses require robust evidence lifecycle management skills to demonstrate value. In turn, this has increased the possibility of using an end-to-end strategy to leverage a life sciences organization's data, proof, and knowledge resources. Thus, aiding in the dismantling of traditional silos and enabling insight-driven decision-making from the product R&D stage to its commercialization. Hence, the rising emphasis on using comprehensive RWE data is propelling the market's growth.Market Restraining Factors
Medical professionals' and researchers' reluctance to depend on real-world studies
Non-randomized observational studies have historically not been seen as appropriate for evaluating novel medical interventions or treatments due to methodological and research design concerns, such as the possibility of confounding and bias. RWE has spread quickly across applications, yet some stakeholders still hesitate to rely on them. For example, although payers have begun employing RWE, they opt to use internal observational data from randomized clinical trials (RCTs) to influence drug coverage choices. Even a study that is robust, well-planned, and non-randomized would be seen as lower-quality evidence in comparison to an RCT that is poorly conceived. These factors are preventing the Real-World Evidence Solutions Market from expanding.Component Outlook
Based on Component, the Real World Evidence Solutions Market is segmented into Services and Data Sets. The segment's growth is linked to the widespread use of real-world evidence services by healthcare organizations and businesses involved in biotechnology and pharmaceuticals. Presently, Syneos Health, IQVIA, and ICON are providing late-phase services like research planning, protocol development, clinical study management & reporting, as well as endwise real-world evidence (RWE) solutions. Real-world evidence (RWE) solutions vendors may have more opportunities to increase their investments during the medication development cycle due to the growing demand for comprehensive evidence services all throughout the product lifetime.Application Outlook
Based on Application, the Real World Evidence Solutions Market is segmented into Drug Development & Approvals, Medical Device Development & Approvals, Reimbursement/Coverage & Regulatory Decision Making, and Post Market Safety & Adverse Events Monitoring. The reimbursement/coverage and regulatory decision making segment recorded a substantial revenue share in the real world evidence solutions market in 2021. The increasing emphasis on clinical value evidence for choices to offer coverage and the rising cost of therapy is responsible for expanding the reimbursement/coverage and regulatory decision-making segment. The post-market safety and adverse event monitoring area are also projected to expand significantly.End-user Outlook
Based on End-user, the Real World Evidence Solutions Market is segmented into Healthcare Companies, Healthcare Payers, Healthcare Providers, and Others. The healthcare companies segment witnessed the maximum revenue share in the real world evidence solutions market in 2021. The surge is linked to the growing significance of RWE studies in determining how well drugs operate in actual situations and mitigating drug recalls. RWE can assist and advance several processes, including determining which patient group will benefit from an intervention the most, assisting with regulatory approvals and completing data from randomized controlled trials, and assisting with reimbursement efforts and expanding usage indications.Therapeutic Area Outlook
Based on Therapeutic Area, the Real World Evidence Solutions Market is segmented into Oncology, Cardiology, Neurology, Diabetes, Respiratory, and Others. The diabetes segment witnessed a significant revenue share in the real world evidence solutions market in 2021. Further understanding of the efficacy and safety of medications for diabetes and certain other diseases for which diabetes can be an underlying causative factor is necessary. This insight, in clinical settings, can be gained by combining data from randomized controlled trials with evidence from real-world settings.Regional Outlook
Based on Region, the Real World Evidence Solutions Market is segmented into North America, Europe, Asia Pacific, and LAMEA. The Asia Pacific segment procured a considerable growth rate in the real world evidence solutions market in 2021. Increased government initiatives to implement RWE studies and numerous contract research organizations (CROs) and contract research manufacturing organizations in nations like China and India are responsible for this region's rise. Additionally predicted to drive market growth is rising consumer desire for better healthcare services.The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include IBM Corporation, Oracle Corporation, Medpace Holdings, Inc., IQVIA Holdings, Inc., ICON plc, PerkinElmer, Inc., Parexel International Corporation (Phoenix Parentco, Inc.), PPD, Inc. (Thermo Fisher Scientific, Inc.), UnitedHealth Group, Inc. (Optum, Inc.), and Syneos Health, Inc.
Strategies deployed in Real World Evidence Solutions Market
- Dec-2022: IBM signed an agreement to acquire Octo, a digital transformation service provider exclusively serving the U.S. federal government. The acquisition would combine the company's consulting expertise and technical capabilities with Octo's team that enable federal clients to transform faster and better serve citizens
- Jul-2022: IBM took over Databand, a leader in data observability software. With this acquisition, the company aimed to strengthen its software portfolio through automation, data, and AI in order to address the full spectrum of observability
- Nov-2021: PerkinElmer unveiled PKeye, a workflow monitor platform for remotely managing and monitoring workflows. The PKeye platform enables the user to monitor the moving of samples efficiently through extraction, quality management, and liquid handling procedures
- Oct-2021: Syneos Health acquired RxDataScience, healthcare-focused data analytics, data management, and Artificial Intelligence (AI) service provider. Together both companies aimed at providing technology-enabled, insights-powered solutions to biopharma customers by integrating RxDataScience's AI and data-science capabilities with its therapeutic expertise
- Sep-2021: Syneos Health took over StudyKIK, technology-enabled clinical trial recruitment, and retention company. The acquisition would enhance Syneos Health’s ability to provide technology-enabled, insight-powered solutions. In addition, both companies would be able to accelerate product development in order to ensure efficiencies in patient recruitment, engagement, access, and diversity
- Sep-2021: IQVIA joined hands with HealthCore, a U.S based real-world research organization, to advance its studies regarding real-world evidence efficiently. The collaboration would allow the company to improve research design and impact of real-world studies with an aim to advance patient health and clinical results
- Jul-2021: ICON plc took over PRA Health Sciences, a contract research organization. Through this acquisition, the company would focus on developing drugs by using data, applying techniques, and identifying a variety of patient populations
- Dec-2020: Syneos Health completed the acquisition of Illingworth Research Group, a provider of clinical research home health services. Through this acquisition, the company aimed at adding new capabilities to its decentralized clinical trial solutions. Furthermore, these solutions would deliver to increase diversity in clinical trials, accessing remote-based patients who have difficulty accessing research sites
- Jan-2020: IBM acquired Envizi, an analytics software provider for environmental performance management. Through this acquisition, the company aimed at helping businesses create resilient and sustainable operations and supply chains
- Oct-2019: Parexel entered into a strategic partnership with HealthVerity, Inc., the service provider for rapid creation, exchange, and management of healthcare and consumer data. With this partnership, the company aimed at expanding Parexel’s network of real-world data (RWD) sources to deliver drug development solutions for customers. Furthermore, it would enable the company to bring new therapies to market by leveraging these studies
- Sep-2018: PAREXEL came into partnership with Datavant, a healthcare technology company focused on enabling the secure de-identification and linking of healthcare datasets. The partnership would allow the company to optimize clinical studies and real-world evidence generation
Scope of the Study
Market Segments Covered in the Report:
By Component
- Services
- Data Set
By Therapeutic Area
- Oncology
- Cardiology
- Neurology
- Diabetes
- Respiratory
- Others
By End-user
- Healthcare Companies
- Healthcare Payers
- Healthcare Providers
- Others
By Application
- Drug Development & Approvals
- Medical Device Development & Approvals
- Reimbursement/Coverage & Regulatory Decision Making
- Post Market Safety & Adverse Events Monitoring
By Geography
North America
- US
- Canada
- Mexico
- Rest of North America
Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- IBM Corporation
- Oracle Corporation
- Medpace Holdings, Inc
- IQVIA Holdings, Inc
- ICON plc
- PerkinElmer, Inc
- Parexel International Corporation (Phoenix Parentco, Inc.)
- PPD, Inc. (Thermo Fisher Scientific, Inc.)
- UnitedHealth Group, Inc. (Optum, Inc.)
- Syneos Health, Inc
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Real World Evidence Solutions Market, by Component
1.4.2 Global Real World Evidence Solutions Market, by Therapeutic Area
1.4.3 Global Real World Evidence Solutions Market, by End-user
1.4.4 Global Real World Evidence Solutions Market, by Application
1.4.5 Global Real World Evidence Solutions Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Scenario and Composition
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies Deployed in Real World Evidence Solutions Market
Chapter 4. Global Real World Evidence Solutions Market by Component
4.1 Global Services Market by Region
4.2 Global Data Set Market by Region
Chapter 5. Global Real World Evidence Solutions Market by Therapeutic Area
5.1 Global Oncology Market by Region
5.2 Global Cardiology Market by Region
5.3 Global Neurology Market by Region
5.4 Global Diabetes Market by Region
5.5 Global Respiratory Market by Region
5.6 Global Others Market by Region
Chapter 6. Global Real World Evidence Solutions Market by End-user
6.1 Global Healthcare Companies Market by Region
6.2 Global Healthcare Payers Market by Region
6.3 Global Healthcare Providers Market by Region
6.4 Global Others Market by Region
Chapter 7. Global Real World Evidence Solutions Market by Application
7.1 Global Drug Development & Approvals Market by Region
7.2 Global Medical Device Development & Approvals Market by Region
7.3 Global Reimbursement/Coverage & Regulatory Decision Making Market by Region
7.4 Global Post Market Safety & Adverse Events Monitoring Market by Region
Chapter 8. Global Real World Evidence Solutions Market by Region
8.1 North America Real World Evidence Solutions Market
8.1.1 North America Real World Evidence Solutions Market by Component
8.1.1.1 North America Services Market by Country
8.1.1.2 North America Data Set Market by Country
8.1.2 North America Real World Evidence Solutions Market by Therapeutic Area
8.1.2.1 North America Oncology Market by Country
8.1.2.2 North America Cardiology Market by Country
8.1.2.3 North America Neurology Market by Country
8.1.2.4 North America Diabetes Market by Country
8.1.2.5 North America Respiratory Market by Country
8.1.2.6 North America Others Market by Country
8.1.3 North America Real World Evidence Solutions Market by End-user
8.1.3.1 North America Healthcare Companies Market by Country
8.1.3.2 North America Healthcare Payers Market by Country
8.1.3.3 North America Healthcare Providers Market by Country
8.1.3.4 North America Others Market by Country
8.1.4 North America Real World Evidence Solutions Market by Application
8.1.4.1 North America Drug Development & Approvals Market by Country
8.1.4.2 North America Medical Device Development & Approvals Market by Country
8.1.4.3 North America Reimbursement/Coverage & Regulatory Decision Making Market by Country
8.1.4.4 North America Post Market Safety & Adverse Events Monitoring Market by Country
8.1.5 North America Real World Evidence Solutions Market by Country
8.1.5.1 US Real World Evidence Solutions Market
8.1.5.1.1 US Real World Evidence Solutions Market by Component
8.1.5.1.2 US Real World Evidence Solutions Market by Therapeutic Area
8.1.5.1.3 US Real World Evidence Solutions Market by End-user
8.1.5.1.4 US Real World Evidence Solutions Market by Application
8.1.5.2 Canada Real World Evidence Solutions Market
8.1.5.2.1 Canada Real World Evidence Solutions Market by Component
8.1.5.2.2 Canada Real World Evidence Solutions Market by Therapeutic Area
8.1.5.2.3 Canada Real World Evidence Solutions Market by End-user
8.1.5.2.4 Canada Real World Evidence Solutions Market by Application
8.1.5.3 Mexico Real World Evidence Solutions Market
8.1.5.3.1 Mexico Real World Evidence Solutions Market by Component
8.1.5.3.2 Mexico Real World Evidence Solutions Market by Therapeutic Area
8.1.5.3.3 Mexico Real World Evidence Solutions Market by End-user
8.1.5.3.4 Mexico Real World Evidence Solutions Market by Application
8.1.5.4 Rest of North America Real World Evidence Solutions Market
8.1.5.4.1 Rest of North America Real World Evidence Solutions Market by Component
8.1.5.4.2 Rest of North America Real World Evidence Solutions Market by Therapeutic Area
8.1.5.4.3 Rest of North America Real World Evidence Solutions Market by End-user
8.1.5.4.4 Rest of North America Real World Evidence Solutions Market by Application
8.2 Europe Real World Evidence Solutions Market
8.2.1 Europe Real World Evidence Solutions Market by Component
8.2.1.1 Europe Services Market by Country
8.2.1.2 Europe Data Set Market by Country
8.2.2 Europe Real World Evidence Solutions Market by Therapeutic Area
8.2.2.1 Europe Oncology Market by Country
8.2.2.2 Europe Cardiology Market by Country
8.2.2.3 Europe Neurology Market by Country
8.2.2.4 Europe Diabetes Market by Country
8.2.2.5 Europe Respiratory Market by Country
8.2.2.6 Europe Others Market by Country
8.2.3 Europe Real World Evidence Solutions Market by End-user
8.2.3.1 Europe Healthcare Companies Market by Country
8.2.3.2 Europe Healthcare Payers Market by Country
8.2.3.3 Europe Healthcare Providers Market by Country
8.2.3.4 Europe Others Market by Country
8.2.4 Europe Real World Evidence Solutions Market by Application
8.2.4.1 Europe Drug Development & Approvals Market by Country
8.2.4.2 Europe Medical Device Development & Approvals Market by Country
8.2.4.3 Europe Reimbursement/Coverage & Regulatory Decision Making Market by Country
8.2.4.4 Europe Post Market Safety & Adverse Events Monitoring Market by Country
8.2.5 Europe Real World Evidence Solutions Market by Country
8.2.5.1 Germany Real World Evidence Solutions Market
8.2.5.1.1 Germany Real World Evidence Solutions Market by Component
8.2.5.1.2 Germany Real World Evidence Solutions Market by Therapeutic Area
8.2.5.1.3 Germany Real World Evidence Solutions Market by End-user
8.2.5.1.4 Germany Real World Evidence Solutions Market by Application
8.2.5.2 UK Real World Evidence Solutions Market
8.2.5.2.1 UK Real World Evidence Solutions Market by Component
8.2.5.2.2 UK Real World Evidence Solutions Market by Therapeutic Area
8.2.5.2.3 UK Real World Evidence Solutions Market by End-user
8.2.5.2.4 UK Real World Evidence Solutions Market by Application
8.2.5.3 France Real World Evidence Solutions Market
8.2.5.3.1 France Real World Evidence Solutions Market by Component
8.2.5.3.2 France Real World Evidence Solutions Market by Therapeutic Area
8.2.5.3.3 France Real World Evidence Solutions Market by End-user
8.2.5.3.4 France Real World Evidence Solutions Market by Application
8.2.5.4 Russia Real World Evidence Solutions Market
8.2.5.4.1 Russia Real World Evidence Solutions Market by Component
8.2.5.4.2 Russia Real World Evidence Solutions Market by Therapeutic Area
8.2.5.4.3 Russia Real World Evidence Solutions Market by End-user
8.2.5.4.4 Russia Real World Evidence Solutions Market by Application
8.2.5.5 Spain Real World Evidence Solutions Market
8.2.5.5.1 Spain Real World Evidence Solutions Market by Component
8.2.5.5.2 Spain Real World Evidence Solutions Market by Therapeutic Area
8.2.5.5.3 Spain Real World Evidence Solutions Market by End-user
8.2.5.5.4 Spain Real World Evidence Solutions Market by Application
8.2.5.6 Italy Real World Evidence Solutions Market
8.2.5.6.1 Italy Real World Evidence Solutions Market by Component
8.2.5.6.2 Italy Real World Evidence Solutions Market by Therapeutic Area
8.2.5.6.3 Italy Real World Evidence Solutions Market by End-user
8.2.5.6.4 Italy Real World Evidence Solutions Market by Application
8.2.5.7 Rest of Europe Real World Evidence Solutions Market
8.2.5.7.1 Rest of Europe Real World Evidence Solutions Market by Component
8.2.5.7.2 Rest of Europe Real World Evidence Solutions Market by Therapeutic Area
8.2.5.7.3 Rest of Europe Real World Evidence Solutions Market by End-user
8.2.5.7.4 Rest of Europe Real World Evidence Solutions Market by Application
8.3 Asia Pacific Real World Evidence Solutions Market
8.3.1 Asia Pacific Real World Evidence Solutions Market by Component
8.3.1.1 Asia Pacific Services Market by Country
8.3.1.2 Asia Pacific Data Set Market by Country
8.3.2 Asia Pacific Real World Evidence Solutions Market by Therapeutic Area
8.3.2.1 Asia Pacific Oncology Market by Country
8.3.2.2 Asia Pacific Cardiology Market by Country
8.3.2.3 Asia Pacific Neurology Market by Country
8.3.2.4 Asia Pacific Diabetes Market by Country
8.3.2.5 Asia Pacific Respiratory Market by Country
8.3.2.6 Asia Pacific Others Market by Country
8.3.3 Asia Pacific Real World Evidence Solutions Market by End-user
8.3.3.1 Asia Pacific Healthcare Companies Market by Country
8.3.3.2 Asia Pacific Healthcare Payers Market by Country
8.3.3.3 Asia Pacific Healthcare Providers Market by Country
8.3.3.4 Asia Pacific Others Market by Country
8.3.4 Asia Pacific Real World Evidence Solutions Market by Application
8.3.4.1 Asia Pacific Drug Development & Approvals Market by Country
8.3.4.2 Asia Pacific Medical Device Development & Approvals Market by Country
8.3.4.3 Asia Pacific Reimbursement/Coverage & Regulatory Decision Making Market by Country
8.3.4.4 Asia Pacific Post Market Safety & Adverse Events Monitoring Market by Country
8.3.5 Asia Pacific Real World Evidence Solutions Market by Country
8.3.5.1 China Real World Evidence Solutions Market
8.3.5.1.1 China Real World Evidence Solutions Market by Component
8.3.5.1.2 China Real World Evidence Solutions Market by Therapeutic Area
8.3.5.1.3 China Real World Evidence Solutions Market by End-user
8.3.5.1.4 China Real World Evidence Solutions Market by Application
8.3.5.2 Japan Real World Evidence Solutions Market
8.3.5.2.1 Japan Real World Evidence Solutions Market by Component
8.3.5.2.2 Japan Real World Evidence Solutions Market by Therapeutic Area
8.3.5.2.3 Japan Real World Evidence Solutions Market by End-user
8.3.5.2.4 Japan Real World Evidence Solutions Market by Application
8.3.5.3 India Real World Evidence Solutions Market
8.3.5.3.1 India Real World Evidence Solutions Market by Component
8.3.5.3.2 India Real World Evidence Solutions Market by Therapeutic Area
8.3.5.3.3 India Real World Evidence Solutions Market by End-user
8.3.5.3.4 India Real World Evidence Solutions Market by Application
8.3.5.4 South Korea Real World Evidence Solutions Market
8.3.5.4.1 South Korea Real World Evidence Solutions Market by Component
8.3.5.4.2 South Korea Real World Evidence Solutions Market by Therapeutic Area
8.3.5.4.3 South Korea Real World Evidence Solutions Market by End-user
8.3.5.4.4 South Korea Real World Evidence Solutions Market by Application
8.3.5.5 Singapore Real World Evidence Solutions Market
8.3.5.5.1 Singapore Real World Evidence Solutions Market by Component
8.3.5.5.2 Singapore Real World Evidence Solutions Market by Therapeutic Area
8.3.5.5.3 Singapore Real World Evidence Solutions Market by End-user
8.3.5.5.4 Singapore Real World Evidence Solutions Market by Application
8.3.5.6 Malaysia Real World Evidence Solutions Market
8.3.5.6.1 Malaysia Real World Evidence Solutions Market by Component
8.3.5.6.2 Malaysia Real World Evidence Solutions Market by Therapeutic Area
8.3.5.6.3 Malaysia Real World Evidence Solutions Market by End-user
8.3.5.6.4 Malaysia Real World Evidence Solutions Market by Application
8.3.5.7 Rest of Asia Pacific Real World Evidence Solutions Market
8.3.5.7.1 Rest of Asia Pacific Real World Evidence Solutions Market by Component
8.3.5.7.2 Rest of Asia Pacific Real World Evidence Solutions Market by Therapeutic Area
8.3.5.7.3 Rest of Asia Pacific Real World Evidence Solutions Market by End-user
8.3.5.7.4 Rest of Asia Pacific Real World Evidence Solutions Market by Application
8.4 LAMEA Real World Evidence Solutions Market
8.4.1 LAMEA Real World Evidence Solutions Market by Component
8.4.1.1 LAMEA Services Market by Country
8.4.1.2 LAMEA Data Set Market by Country
8.4.2 LAMEA Real World Evidence Solutions Market by Therapeutic Area
8.4.2.1 LAMEA Oncology Market by Country
8.4.2.2 LAMEA Cardiology Market by Country
8.4.2.3 LAMEA Neurology Market by Country
8.4.2.4 LAMEA Diabetes Market by Country
8.4.2.5 LAMEA Respiratory Market by Country
8.4.2.6 LAMEA Others Market by Country
8.4.3 LAMEA Real World Evidence Solutions Market by End-user
8.4.3.1 LAMEA Healthcare Companies Market by Country
8.4.3.2 LAMEA Healthcare Payers Market by Country
8.4.3.3 LAMEA Healthcare Providers Market by Country
8.4.3.4 LAMEA Others Market by Country
8.4.4 LAMEA Real World Evidence Solutions Market by Application
8.4.4.1 LAMEA Drug Development & Approvals Market by Country
8.4.4.2 LAMEA Medical Device Development & Approvals Market by Country
8.4.4.3 LAMEA Reimbursement/Coverage & Regulatory Decision Making Market by Country
8.4.4.4 LAMEA Post Market Safety & Adverse Events Monitoring Market by Country
8.4.5 LAMEA Real World Evidence Solutions Market by Country
8.4.5.1 Brazil Real World Evidence Solutions Market
8.4.5.1.1 Brazil Real World Evidence Solutions Market by Component
8.4.5.1.2 Brazil Real World Evidence Solutions Market by Therapeutic Area
8.4.5.1.3 Brazil Real World Evidence Solutions Market by End-user
8.4.5.1.4 Brazil Real World Evidence Solutions Market by Application
8.4.5.2 Argentina Real World Evidence Solutions Market
8.4.5.2.1 Argentina Real World Evidence Solutions Market by Component
8.4.5.2.2 Argentina Real World Evidence Solutions Market by Therapeutic Area
8.4.5.2.3 Argentina Real World Evidence Solutions Market by End-user
8.4.5.2.4 Argentina Real World Evidence Solutions Market by Application
8.4.5.3 UAE Real World Evidence Solutions Market
8.4.5.3.1 UAE Real World Evidence Solutions Market by Component
8.4.5.3.2 UAE Real World Evidence Solutions Market by Therapeutic Area
8.4.5.3.3 UAE Real World Evidence Solutions Market by End-user
8.4.5.3.4 UAE Real World Evidence Solutions Market by Application
8.4.5.4 Saudi Arabia Real World Evidence Solutions Market
8.4.5.4.1 Saudi Arabia Real World Evidence Solutions Market by Component
8.4.5.4.2 Saudi Arabia Real World Evidence Solutions Market by Therapeutic Area
8.4.5.4.3 Saudi Arabia Real World Evidence Solutions Market by End-user
8.4.5.4.4 Saudi Arabia Real World Evidence Solutions Market by Application
8.4.5.5 South Africa Real World Evidence Solutions Market
8.4.5.5.1 South Africa Real World Evidence Solutions Market by Component
8.4.5.5.2 South Africa Real World Evidence Solutions Market by Therapeutic Area
8.4.5.5.3 South Africa Real World Evidence Solutions Market by End-user
8.4.5.5.4 South Africa Real World Evidence Solutions Market by Application
8.4.5.6 Nigeria Real World Evidence Solutions Market
8.4.5.6.1 Nigeria Real World Evidence Solutions Market by Component
8.4.5.6.2 Nigeria Real World Evidence Solutions Market by Therapeutic Area
8.4.5.6.3 Nigeria Real World Evidence Solutions Market by End-user
8.4.5.6.4 Nigeria Real World Evidence Solutions Market by Application
8.4.5.7 Rest of LAMEA Real World Evidence Solutions Market
8.4.5.7.1 Rest of LAMEA Real World Evidence Solutions Market by Component
8.4.5.7.2 Rest of LAMEA Real World Evidence Solutions Market by Therapeutic Area
8.4.5.7.3 Rest of LAMEA Real World Evidence Solutions Market by End-user
8.4.5.7.4 Rest of LAMEA Real World Evidence Solutions Market by Application
Chapter 9. Company Profiles
9.1 IBM Corporation
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Regional & Segmental Analysis
9.1.4 Research & Development Expenses
9.1.5 Recent strategies and developments:
9.1.5.1 Acquisition and Mergers:
9.1.6 SWOT Analysis
9.2 Oracle Corporation
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expense
9.2.5 SWOT Analysis
9.3 PPD, Inc. (Thermo Fisher Scientific, Inc.)
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Segmental and Regional Analysis
9.3.4 Research & Development Expense
9.3.5 SWOT Analysis
9.4 UnitedHealth Group, Inc. (Optum, Inc.)
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Segmental Analysis
9.5 Syneos Health, Inc.
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Recent strategies and developments:
9.5.4.1 Acquisition and Mergers:
9.6 IQVIA Holdings, Inc.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Segmental and Regional Analysis
9.6.4 Recent strategies and developments:
9.6.4.1 Partnerships, Collaborations, and Agreements:
9.6.4.2 Acquisition and Mergers:
9.7 Medpace Holdings, Inc.
9.7.1 Company Overview
9.7.2 Financial Analysis
9.8 ICON plc
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Regional Analysis
9.8.4 Recent strategies and developments:
9.8.4.1 Acquisition and Mergers:
9.9 PerkinElmer, Inc.
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Segmental and Regional Analysis
9.9.4 Research & Development Expense
9.9.5 Recent strategies and developments:
9.9.5.1 Product Launches and Product Expansions:
9.10. Parexel International Corporation (Phoenix Parentco, Inc.)
9.10.1 Company Overview
9.10.2 Recent strategies and developments:
9.10.2.1 Partnerships, Collaborations, and Agreements:
Companies Mentioned
- IBM Corporation
- Oracle Corporation
- Medpace Holdings, Inc.
- IQVIA Holdings, Inc.
- ICON plc
- PerkinElmer, Inc.
- Parexel International Corporation (Phoenix Parentco, Inc.)
- PPD, Inc. (Thermo Fisher Scientific, Inc.)
- UnitedHealth Group, Inc. (Optum, Inc.)
- Syneos Health, Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 293 |
| Published | January 2023 |
| Forecast Period | 2021 - 2028 |
| Estimated Market Value ( USD | $ 38527.1 Million |
| Forecasted Market Value ( USD | $ 65133.8 Million |
| Compound Annual Growth Rate | 8.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
